ADC Therapy and Clinical Trials in China: Targets and Risks
Clinical Trials & Advanced Therapies
Antibody-drug conjugates (ADCs) combine a targeted antibody with a cytotoxic payload. They have changed outcomes in several solid tumours and lymphomas, and China now runs a substantial number of ADC trials, both with domestic candidates and as a site for global studies. For a patient considering this route, the practical questions are about eligibility and verification, not enthusiasm.
How eligibility is usually framed
- Confirmed histology, with the target antigen expressed — testing method matters, and not every laboratory uses the same assay.
- A defined number of prior lines of therapy, often including a specific class of agent.
- Adequate organ function: bone marrow reserve, liver enzymes, cardiac function for some payloads.
- No exclusion conditions such as active interstitial lung disease, uncontrolled infection or prior severe toxicity to a related drug.
Risks that need to be discussed explicitly
ADCs carry class-specific toxicities: interstitial lung disease with some agents, ocular surface toxicity with others, peripheral neuropathy, and myelosuppression. The precise profile depends on the payload and linker, so a blanket statement that "ADCs are well tolerated" is not useful. Ask for the specific adverse-event profile of the exact compound in the protocol.
How to verify what is actually available
- Ask for the trial registration number and read the public record: phase, status, eligibility criteria, recruiting sites.
- Confirm that the site named is recruiting, rather than pending ethics approval.
- Ask whether the study is randomised and what the comparator arm is.
- Ask who pays for the drug, the tests and any hospital costs not covered by the sponsor.
Realistic expectations
Enrolment is competitive and screening can take two to four weeks, with no guarantee of entry. A trial is a treatment option to be evaluated, not a guaranteed route. Patients who keep a parallel standard-of-care plan move forward regardless of the screening result.
Next step: send your pathology report and treatment history, and we will tell you which target testing would be needed before a trial team could assess you.
